| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 25 | 2019 | 2209 | 2.13 | Why? |
| HIV Infections | 54 | 2020 | 11620 | 1.91 | Why? |
| HIV-1 | 27 | 2019 | 3365 | 1.90 | Why? |
| Anti-Retroviral Agents | 10 | 2020 | 1099 | 1.50 | Why? |
| Antiretroviral Therapy, Highly Active | 18 | 2019 | 952 | 1.07 | Why? |
| Parkinson Disease | 8 | 2019 | 1414 | 1.02 | Why? |
| Reverse Transcriptase Inhibitors | 6 | 2020 | 309 | 0.87 | Why? |
| Cognitive Dysfunction | 8 | 2021 | 1389 | 0.79 | Why? |
| Myeloid-Derived Suppressor Cells | 6 | 2020 | 316 | 0.77 | Why? |
| CD4 Lymphocyte Count | 13 | 2020 | 1517 | 0.70 | Why? |
| Hepatitis C | 7 | 2019 | 1514 | 0.64 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.62 | Why? |
| Sofosbuvir | 3 | 2018 | 518 | 0.62 | Why? |
| Cerebral Cortex | 2 | 2019 | 276 | 0.61 | Why? |
| Darunavir | 5 | 2018 | 477 | 0.57 | Why? |
| HIV Integrase Inhibitors | 4 | 2020 | 173 | 0.55 | Why? |
| HIV Reverse Transcriptase | 3 | 2019 | 104 | 0.54 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.53 | Why? |
| Encephalitis | 3 | 2021 | 797 | 0.50 | Why? |
| Cerebellum | 2 | 2018 | 119 | 0.49 | Why? |
| REM Sleep Behavior Disorder | 2 | 2019 | 24 | 0.48 | Why? |
| Lamivudine | 6 | 2019 | 210 | 0.47 | Why? |
| Cognition Disorders | 3 | 2018 | 574 | 0.47 | Why? |
| Viral Load | 24 | 2020 | 15850 | 0.47 | Why? |
| Atazanavir Sulfate | 3 | 2018 | 213 | 0.45 | Why? |
| Heterocyclic Compounds, 3-Ring | 5 | 2020 | 275 | 0.44 | Why? |
| Serotonergic Neurons | 1 | 2019 | 3 | 0.41 | Why? |
| Lewy Body Disease | 1 | 2019 | 36 | 0.39 | Why? |
| Pyridones | 6 | 2020 | 738 | 0.39 | Why? |
| Dopaminergic Neurons | 1 | 2019 | 59 | 0.38 | Why? |
| Supranuclear Palsy, Progressive | 2 | 2019 | 20 | 0.38 | Why? |
| Ritonavir | 10 | 2020 | 4212 | 0.38 | Why? |
| HIV Protease Inhibitors | 5 | 2019 | 434 | 0.37 | Why? |
| Hypotension, Orthostatic | 1 | 2019 | 55 | 0.37 | Why? |
| Drug Resistance, Viral | 4 | 2019 | 1083 | 0.37 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.37 | Why? |
| Glucosylceramidase | 1 | 2017 | 11 | 0.36 | Why? |
| Coinfection | 11 | 2021 | 6820 | 0.36 | Why? |
| Oxazines | 5 | 2020 | 279 | 0.35 | Why? |
| HIV Seropositivity | 3 | 2019 | 320 | 0.35 | Why? |
| Urination Disorders | 1 | 2017 | 10 | 0.35 | Why? |
| Brain Stem | 1 | 2018 | 131 | 0.34 | Why? |
| Fluorodeoxyglucose F18 | 3 | 2018 | 1153 | 0.34 | Why? |
| Tenofovir | 6 | 2020 | 449 | 0.33 | Why? |
| Tomography, Emission-Computed, Single-Photon | 1 | 2019 | 279 | 0.33 | Why? |
| tau Proteins | 1 | 2017 | 162 | 0.33 | Why? |
| Piperazines | 5 | 2020 | 445 | 0.32 | Why? |
| Prodromal Symptoms | 1 | 2017 | 133 | 0.32 | Why? |
| Amyloid beta-Peptides | 1 | 2017 | 185 | 0.31 | Why? |
| Frontotemporal Dementia | 2 | 2017 | 55 | 0.30 | Why? |
| Italy | 27 | 2021 | 38444 | 0.30 | Why? |
| Drug Substitution | 2 | 2018 | 385 | 0.27 | Why? |
| White Matter | 1 | 2018 | 369 | 0.27 | Why? |
| Middle Aged | 71 | 2021 | 270681 | 0.27 | Why? |
| Male | 87 | 2021 | 367725 | 0.27 | Why? |
| Triazoles | 2 | 2019 | 440 | 0.27 | Why? |
| Hepatitis C, Chronic | 3 | 2018 | 973 | 0.26 | Why? |
| Female | 85 | 2021 | 380317 | 0.26 | Why? |
| Heparin, Low-Molecular-Weight | 3 | 2021 | 1731 | 0.25 | Why? |
| Accidental Falls | 1 | 2018 | 448 | 0.25 | Why? |
| Peptide Fragments | 2 | 2019 | 2075 | 0.25 | Why? |
| Radiopharmaceuticals | 3 | 2019 | 763 | 0.25 | Why? |
| Neural Pathways | 2 | 2019 | 155 | 0.24 | Why? |
| Raltegravir Potassium | 3 | 2019 | 132 | 0.24 | Why? |
| Drug Therapy, Combination | 12 | 2018 | 7268 | 0.24 | Why? |
| Lymphocyte Activation | 4 | 2020 | 2742 | 0.23 | Why? |
| Psoas Muscles | 1 | 2021 | 28 | 0.23 | Why? |
| Treatment Failure | 8 | 2019 | 2106 | 0.23 | Why? |
| Viremia | 3 | 2018 | 1020 | 0.23 | Why? |
| CD4-Positive T-Lymphocytes | 5 | 2020 | 4545 | 0.23 | Why? |
| Chlamydophila pneumoniae | 1 | 2021 | 98 | 0.21 | Why? |
| Akinetic Mutism | 1 | 2020 | 31 | 0.21 | Why? |
| Positron-Emission Tomography | 3 | 2018 | 802 | 0.21 | Why? |
| Humans | 105 | 2021 | 930598 | 0.21 | Why? |
| Perforin | 1 | 2020 | 136 | 0.21 | Why? |
| Neuropsychological Tests | 5 | 2018 | 954 | 0.20 | Why? |
| Sirtuin 1 | 1 | 2021 | 100 | 0.20 | Why? |
| Iron Overload | 1 | 2021 | 113 | 0.19 | Why? |
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2018 | 2 | 0.19 | Why? |
| T-Lymphocytes, Cytotoxic | 2 | 2020 | 552 | 0.19 | Why? |
| DNA, Viral | 3 | 2018 | 2521 | 0.19 | Why? |
| Activities of Daily Living | 2 | 2018 | 1530 | 0.19 | Why? |
| HIV Integrase | 1 | 2019 | 67 | 0.19 | Why? |
| CD8-Positive T-Lymphocytes | 5 | 2020 | 5837 | 0.19 | Why? |
| Hepatitis B Surface Antigens | 2 | 2019 | 305 | 0.19 | Why? |
| Thrombophilia | 2 | 2021 | 1935 | 0.18 | Why? |
| Stem Cell Factor | 1 | 2018 | 12 | 0.18 | Why? |
| Lymphoma, AIDS-Related | 1 | 2017 | 13 | 0.18 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2021 | 310 | 0.18 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.18 | Why? |
| Practice Guidelines as Topic | 2 | 2017 | 15421 | 0.18 | Why? |
| Hematoma | 1 | 2021 | 305 | 0.18 | Why? |
| Cyclohexanes | 1 | 2017 | 43 | 0.17 | Why? |
| Aged | 39 | 2021 | 215776 | 0.17 | Why? |
| Pneumonia, Mycoplasma | 1 | 2021 | 292 | 0.17 | Why? |
| Liver Failure | 1 | 2021 | 266 | 0.17 | Why? |
| Emtricitabine | 4 | 2018 | 202 | 0.17 | Why? |
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 47 | 0.17 | Why? |
| Chemokine CCL4 | 1 | 2017 | 71 | 0.17 | Why? |
| Cerebrospinal Fluid | 1 | 2019 | 234 | 0.17 | Why? |
| Magnetic Resonance Imaging | 7 | 2021 | 6551 | 0.16 | Why? |
| Adult | 49 | 2021 | 244371 | 0.16 | Why? |
| Hepatitis C Antibodies | 1 | 2017 | 120 | 0.16 | Why? |
| HIV Protease | 1 | 2017 | 86 | 0.16 | Why? |
| Homeostasis | 1 | 2021 | 582 | 0.16 | Why? |
| Connectome | 1 | 2017 | 67 | 0.16 | Why? |
| Inflammation | 5 | 2020 | 13255 | 0.16 | Why? |
| HIV Envelope Protein gp120 | 1 | 2019 | 267 | 0.16 | Why? |
| Transgender Persons | 1 | 2020 | 322 | 0.16 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.15 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| HIV | 3 | 2018 | 1116 | 0.15 | Why? |
| Interleukin-18 | 1 | 2018 | 328 | 0.15 | Why? |
| Brain Ischemia | 2 | 2021 | 2813 | 0.15 | Why? |
| Guidelines as Topic | 2 | 2019 | 2844 | 0.15 | Why? |
| Cyclopropanes | 4 | 2019 | 332 | 0.15 | Why? |
| Glomerular Filtration Rate | 2 | 2020 | 1262 | 0.15 | Why? |
| Olfaction Disorders | 2 | 2021 | 3704 | 0.15 | Why? |
| Flow Cytometry | 3 | 2018 | 2393 | 0.14 | Why? |
| Hematopoietic Stem Cells | 1 | 2018 | 321 | 0.14 | Why? |
| Cytokines | 9 | 2021 | 15010 | 0.14 | Why? |
| Risk | 3 | 2020 | 5288 | 0.14 | Why? |
| Cryopreservation | 1 | 2018 | 464 | 0.14 | Why? |
| Habits | 1 | 2017 | 334 | 0.14 | Why? |
| Medication Adherence | 3 | 2018 | 1270 | 0.14 | Why? |
| Inpatients | 2 | 2021 | 5161 | 0.14 | Why? |
| Drug Administration Schedule | 3 | 2017 | 2324 | 0.14 | Why? |
| Copper | 1 | 2018 | 288 | 0.14 | Why? |
| Lectins | 1 | 2017 | 311 | 0.14 | Why? |
| Frontotemporal Lobar Degeneration | 1 | 2013 | 20 | 0.14 | Why? |
| Gray Matter | 1 | 2015 | 150 | 0.14 | Why? |
| 2-Naphthylamine | 3 | 2018 | 54 | 0.14 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.13 | Why? |
| Dementia | 2 | 2018 | 1861 | 0.13 | Why? |
| Hospital Mortality | 7 | 2021 | 22087 | 0.13 | Why? |
| Treatment Outcome | 18 | 2021 | 51732 | 0.13 | Why? |
| Macrocyclic Compounds | 3 | 2018 | 78 | 0.13 | Why? |
| Uracil | 3 | 2018 | 101 | 0.13 | Why? |
| Lactams, Macrocyclic | 3 | 2018 | 130 | 0.13 | Why? |
| Mutation | 3 | 2018 | 12376 | 0.12 | Why? |
| Biological Evolution | 1 | 2018 | 641 | 0.12 | Why? |
| Disease Progression | 6 | 2020 | 13580 | 0.12 | Why? |
| RNA, Viral | 11 | 2021 | 32276 | 0.12 | Why? |
| Severity of Illness Index | 10 | 2021 | 48226 | 0.12 | Why? |
| Proportional Hazards Models | 7 | 2021 | 6543 | 0.12 | Why? |
| Lymphoma | 1 | 2017 | 522 | 0.12 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.12 | Why? |
| Brain | 2 | 2018 | 5133 | 0.12 | Why? |
| Psychometrics | 1 | 2019 | 1269 | 0.11 | Why? |
| Antiviral Agents | 8 | 2021 | 41703 | 0.11 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 245 | 0.11 | Why? |
| Valine | 3 | 2018 | 359 | 0.11 | Why? |
| Tuberculosis | 2 | 2018 | 2895 | 0.11 | Why? |
| Nervous System Diseases | 2 | 2020 | 4092 | 0.11 | Why? |
| Leukocytes, Mononuclear | 2 | 2018 | 2115 | 0.11 | Why? |
| Aged, 80 and over | 15 | 2021 | 88759 | 0.11 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.11 | Why? |
| Survival Analysis | 6 | 2021 | 7592 | 0.11 | Why? |
| Proline | 3 | 2018 | 345 | 0.11 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2018 | 665 | 0.11 | Why? |
| Lymphocytes | 2 | 2021 | 3056 | 0.11 | Why? |
| Blood Transfusion | 1 | 2020 | 1399 | 0.11 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.11 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.11 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.10 | Why? |
| Plasma | 2 | 2019 | 1809 | 0.10 | Why? |
| Statistics, Nonparametric | 2 | 2017 | 1008 | 0.10 | Why? |
| Tropanes | 1 | 2019 | 18 | 0.10 | Why? |
| Substantia Nigra | 1 | 2019 | 22 | 0.10 | Why? |
| Retrospective Studies | 19 | 2021 | 105322 | 0.10 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.10 | Why? |
| Carbamates | 3 | 2018 | 485 | 0.10 | Why? |
| Sulfonamides | 4 | 2021 | 1294 | 0.10 | Why? |
| Liver | 2 | 2021 | 4007 | 0.10 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.10 | Why? |
| Rome | 2 | 2021 | 497 | 0.10 | Why? |
| Longitudinal Studies | 5 | 2021 | 9893 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.10 | Why? |
| Thalamus | 1 | 2019 | 75 | 0.10 | Why? |
| Electroencephalography | 2 | 2021 | 1242 | 0.10 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Kaplan-Meier Estimate | 4 | 2021 | 4260 | 0.09 | Why? |
| Time | 1 | 2021 | 631 | 0.09 | Why? |
| Lopinavir | 3 | 2020 | 4308 | 0.09 | Why? |
| Drug Combinations | 4 | 2020 | 3852 | 0.09 | Why? |
| Postural Balance | 1 | 2019 | 144 | 0.09 | Why? |
| Cognition | 1 | 2017 | 1394 | 0.09 | Why? |
| Comorbidity | 9 | 2021 | 34796 | 0.09 | Why? |
| Cohort Studies | 10 | 2021 | 36005 | 0.09 | Why? |
| Case-Control Studies | 6 | 2021 | 17671 | 0.09 | Why? |
| Neurologic Examination | 1 | 2021 | 428 | 0.09 | Why? |
| Respiratory System | 1 | 2021 | 3213 | 0.09 | Why? |
| Neuroimaging | 1 | 2015 | 1106 | 0.09 | Why? |
| Glucocorticoids | 2 | 2021 | 4431 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Alzheimer Disease | 1 | 2018 | 1020 | 0.09 | Why? |
| Urological Agents | 1 | 2017 | 24 | 0.09 | Why? |
| Stroke | 2 | 2021 | 8839 | 0.09 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.08 | Why? |
| Cobicistat | 2 | 2019 | 172 | 0.08 | Why? |
| Tablets | 2 | 2018 | 219 | 0.08 | Why? |
| Regression Analysis | 3 | 2019 | 2484 | 0.08 | Why? |
| Anilides | 2 | 2018 | 105 | 0.08 | Why? |
| Quinolones | 2 | 2019 | 167 | 0.08 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.08 | Why? |
| CD4-CD8 Ratio | 2 | 2018 | 235 | 0.08 | Why? |
| Antiparkinson Agents | 1 | 2017 | 125 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.08 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Interferon-gamma | 3 | 2020 | 2711 | 0.07 | Why? |
| Intubation, Intratracheal | 1 | 2021 | 3962 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.07 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.07 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.07 | Why? |
| Liver Diseases | 1 | 2019 | 2698 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Lipodystrophy | 1 | 2002 | 18 | 0.06 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| Prevalence | 5 | 2021 | 25773 | 0.06 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.06 | Why? |
| Glial Fibrillary Acidic Protein | 1 | 2021 | 138 | 0.06 | Why? |
| Self Report | 2 | 2019 | 3802 | 0.06 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Reproducibility of Results | 3 | 2019 | 11304 | 0.05 | Why? |
| Nitric Oxide Synthase Type II | 1 | 2020 | 119 | 0.05 | Why? |
| beta 2-Microglobulin | 1 | 2020 | 102 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.05 | Why? |
| Ribavirin | 2 | 2018 | 1182 | 0.05 | Why? |
| Delavirdine | 1 | 2019 | 5 | 0.05 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.05 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.05 | Why? |
| Alkynes | 1 | 2019 | 98 | 0.05 | Why? |
| Erythrocyte Indices | 1 | 2020 | 207 | 0.05 | Why? |
| Dideoxynucleosides | 1 | 2019 | 92 | 0.05 | Why? |
| Nevirapine | 1 | 2019 | 57 | 0.05 | Why? |
| Mean Platelet Volume | 1 | 2020 | 203 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2021 | 233 | 0.05 | Why? |
| Republic of Belarus | 1 | 2018 | 24 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Rilpivirine | 1 | 2019 | 65 | 0.05 | Why? |
| Reperfusion | 1 | 2021 | 491 | 0.05 | Why? |
| Benzoxazines | 1 | 2019 | 103 | 0.05 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.05 | Why? |
| Sequence Analysis, RNA | 2 | 2018 | 2290 | 0.05 | Why? |
| Tissue Fixation | 1 | 2018 | 85 | 0.05 | Why? |
| Pyridazines | 1 | 2019 | 86 | 0.05 | Why? |
| HIV Long Terminal Repeat | 1 | 2017 | 16 | 0.05 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.05 | Why? |
| Virulence Factors | 1 | 2021 | 338 | 0.05 | Why? |
| Transforming Growth Factor beta | 1 | 2020 | 363 | 0.04 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.04 | Why? |
| Proviruses | 1 | 2018 | 82 | 0.04 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 139 | 0.04 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.04 | Why? |
| AIDS Dementia Complex | 1 | 2018 | 48 | 0.04 | Why? |
| Hepatocytes | 1 | 2021 | 549 | 0.04 | Why? |
| Basal Ganglia | 1 | 2017 | 49 | 0.04 | Why? |
| HIV Antigens | 1 | 2018 | 102 | 0.04 | Why? |
| Adaptation, Biological | 1 | 2018 | 179 | 0.04 | Why? |
| Mental Status and Dementia Tests | 1 | 2018 | 208 | 0.04 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.04 | Why? |
| Bone Marrow | 1 | 2020 | 492 | 0.04 | Why? |
| Adipose Tissue | 1 | 2002 | 612 | 0.04 | Why? |
| Henipavirus Infections | 1 | 2018 | 122 | 0.04 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.04 | Why? |
| Spleen | 1 | 2020 | 877 | 0.04 | Why? |
| Body Fluids | 1 | 2020 | 451 | 0.04 | Why? |
| Longevity | 1 | 2018 | 159 | 0.04 | Why? |
| Adenine | 1 | 2019 | 463 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.04 | Why? |
| Muscular Diseases | 1 | 2021 | 392 | 0.04 | Why? |
| Coffee | 1 | 2017 | 79 | 0.04 | Why? |
| Nerve Net | 1 | 2017 | 118 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Prognosis | 4 | 2021 | 32490 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Testosterone | 1 | 2021 | 596 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2018 | 360 | 0.04 | Why? |
| Iron | 1 | 2021 | 619 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2020 | 992 | 0.04 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.04 | Why? |
| Odds Ratio | 2 | 2017 | 5861 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Purines | 1 | 2021 | 816 | 0.04 | Why? |
| Antigens, Bacterial | 1 | 2018 | 330 | 0.04 | Why? |
| Atrophy | 1 | 2015 | 192 | 0.04 | Why? |
| Blood Cell Count | 1 | 2020 | 1101 | 0.04 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.04 | Why? |
| Azetidines | 1 | 2021 | 722 | 0.04 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.03 | Why? |
| Liver Function Tests | 1 | 2021 | 1325 | 0.03 | Why? |
| Th1 Cells | 1 | 2020 | 1228 | 0.03 | Why? |
| Automation, Laboratory | 1 | 2017 | 536 | 0.03 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 290 | 0.03 | Why? |
| GTPase-Activating Proteins | 1 | 2013 | 36 | 0.03 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2020 | 1329 | 0.03 | Why? |
| Protein Structure, Tertiary | 1 | 2018 | 1565 | 0.03 | Why? |
| Mitochondria | 1 | 2021 | 857 | 0.03 | Why? |
| Neutrophils | 2 | 2020 | 5476 | 0.03 | Why? |
| Nitriles | 1 | 2019 | 1053 | 0.03 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2017 | 669 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Pyrrolidines | 1 | 2017 | 558 | 0.03 | Why? |
| Demography | 1 | 2020 | 1660 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2020 | 1394 | 0.03 | Why? |
| Stem Cells | 1 | 2019 | 595 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2020 | 22971 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Informed Consent | 1 | 2020 | 890 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Positive-Pressure Respiration | 1 | 2021 | 1160 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Compassionate Use Trials | 1 | 2017 | 632 | 0.03 | Why? |
| Algorithms | 2 | 2021 | 7346 | 0.03 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.03 | Why? |
| Geriatric Assessment | 1 | 2021 | 1372 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Biopsy | 1 | 2021 | 2811 | 0.03 | Why? |
| Vascular Diseases | 1 | 2020 | 846 | 0.03 | Why? |
| Withholding Treatment | 1 | 2018 | 798 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2017 | 1031 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.03 | Why? |
| London | 1 | 2018 | 2166 | 0.03 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.03 | Why? |
| Psychiatric Status Rating Scales | 1 | 2018 | 1340 | 0.03 | Why? |
| Pyrimidines | 1 | 2019 | 1557 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Denmark | 1 | 2018 | 2654 | 0.03 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.03 | Why? |
| Pyrazoles | 1 | 2021 | 1791 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.02 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.02 | Why? |
| Thrombectomy | 1 | 2021 | 2272 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.02 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.02 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.02 | Why? |
| Image Processing, Computer-Assisted | 1 | 2017 | 1383 | 0.02 | Why? |
| Peptides | 1 | 2020 | 2513 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.02 | Why? |
| Immune Evasion | 1 | 2018 | 2081 | 0.02 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.02 | Why? |
| Amides | 1 | 2019 | 1864 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.02 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Leukocytes | 1 | 2013 | 1046 | 0.02 | Why? |
| Ambulatory Care Facilities | 1 | 2018 | 2063 | 0.02 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2019 | 3691 | 0.02 | Why? |
| Alcohol Drinking | 1 | 2017 | 1663 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.02 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2018 | 6902 | 0.02 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.02 | Why? |
| Depression | 1 | 2017 | 14116 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.01 | Why? |
| Phenotype | 1 | 2013 | 4037 | 0.01 | Why? |
| Gene Expression Profiling | 1 | 2013 | 3788 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Alanine | 1 | 2019 | 5687 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.01 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.01 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| RNA, Messenger | 1 | 2013 | 5131 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Probability | 1 | 2002 | 923 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2013 | 6740 | 0.01 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.01 | Why? |
| Virus Replication | 1 | 2019 | 14331 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Sex Distribution | 1 | 2002 | 2083 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2002 | 3776 | 0.01 | Why? |
| Age Distribution | 1 | 2002 | 3567 | 0.01 | Why? |
| Mental Disorders | 1 | 2015 | 6742 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2002 | 5440 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |